← All trials
NCT05965219
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2023
- Primary completion
- Jan 1, 2024
- Completion date
- Jan 1, 2024
- First posted
- Jul 28, 2023
- Last posted
- Sep 14, 2023
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cerevel Therapeutics, LLCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.